<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517904</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0093</org_study_id>
    <nct_id>NCT03517904</nct_id>
  </id_info>
  <brief_title>Comparison of Intravascular Ultrasound-Guided vs. Angiography-guided Angioplasty and Dual-antiplatelet v. Triple-antiplatelet Therapy for Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease (IVUS-DCB)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, randomized, controlled, multi-center study&#xD;
&#xD;
        -  A total of 240 subjects with femoropopliteal artery disease will be included according&#xD;
           to inclusion and exclusion criteria.&#xD;
&#xD;
        -  Patients will be randomized in a 1:1 manner into IVUS-guided or angiography-guided&#xD;
           intervention group.&#xD;
&#xD;
        -  Second 1:1 randomization into dual antiplatelet therapy (aspirin + clopidogrel) or&#xD;
           triple antiplatelet therapy (aspirin + clopidogrel + cilostazol) is optional&#xD;
&#xD;
        -  All patients will be treated with drug-coated balloons (In.PACT Admiral) for&#xD;
           femoropopliteal lesions.&#xD;
&#xD;
        -  Bare metal self-expandable stents will be used in addition according to findings of IVUS&#xD;
           or angiography such as severity of arterial dissection or residual stenosis.&#xD;
&#xD;
        -  Patients will be followed clinically for 1 year after the procedure.&#xD;
&#xD;
        -  Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be&#xD;
           performed at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedures lesion stenosis degree</measure>
    <time_frame>at 12 months</time_frame>
    <description>Absence of restenosis &gt;50% by Duplex ultrasound, CT angiography, or catheter-based angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival free from target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Survival free from repeat intervention or surgical treatment due to loss of patency at the target vessel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Femoropopliteal Artery Disease</condition>
  <arm_group>
    <arm_group_label>IVUS-guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravascular ultrasound-guided intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiography-guided group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Angiography-guided intervention group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVUS-guided angioplasty</intervention_name>
    <description>Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.</description>
    <arm_group_label>IVUS-guided group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Angiography-guided angioplasty</intervention_name>
    <description>Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.</description>
    <arm_group_label>Angiography-guided group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19 years or older&#xD;
&#xD;
          -  Symptomatic peripheral artery disease:&#xD;
&#xD;
               -  Moderate or severe claudication (Rutherford category 2 or 3)&#xD;
&#xD;
               -  Critical limb ischemia (Rutherford category 4 or 5)&#xD;
&#xD;
          -  Femoropopliteal artery disease (stenosis &gt; 50%)&#xD;
&#xD;
          -  ABI &lt;0.9&#xD;
&#xD;
          -  Patients with signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute critical limb ischemia&#xD;
&#xD;
          -  Severe critical limb ischemia (Rutherford category 6)&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to any of the following medications:&#xD;
             heparin, aspirin, clopidogrel, cilostazol, or contrast agents&#xD;
&#xD;
          -  Patients requiring oral anticoagulation using warfarin or NOAC&#xD;
&#xD;
          -  Age &gt; 85 years&#xD;
&#xD;
          -  Severe hepatic dysfunction (&gt; 3 times normal reference values)&#xD;
&#xD;
          -  Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding&#xD;
             diathesis&#xD;
&#xD;
          -  LVEF &lt; 40% or clinically overt congestive heart failure&#xD;
&#xD;
          -  Pregnant women or women with potential childbearing&#xD;
&#xD;
          -  Life expectancy &lt;1 year due to comorbidity&#xD;
&#xD;
          -  Previous bypass surgery or stenting in the target femoropopliteal artery&#xD;
&#xD;
          -  Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more&#xD;
             than 50% stenosis or occlusion)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YoungGuk Ko, MD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>ygko@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Femoropopliteal artery disease, drug-coated balloon, angioplasty, antiplatelet therapy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

